iifl-logo-icon 1

Kabra Drugs Ltd Share Price

9.14
(4.94%)
Sep 16, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open9.14
  • Day's High9.14
  • 52 Wk High9.14
  • Prev. Close8.71
  • Day's Low9.14
  • 52 Wk Low 3.2
  • Turnover (lac)0.11
  • P/E0
  • Face Value10
  • Book Value4.19
  • EPS0
  • Mkt. Cap (Cr.)9.21
  • Div. Yield0
View All Historical Data
No Records Found

Kabra Drugs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

9.14

Prev. Close

8.71

Turnover(Lac.)

0.11

Day's High

9.14

Day's Low

9.14

52 Week's High

9.14

52 Week's Low

3.2

Book Value

4.19

Face Value

10

Mkt Cap (₹ Cr.)

9.21

P/E

0

EPS

0

Divi. Yield

0

Kabra Drugs Ltd Corporate Action

23 Jan 2024

12:00 AM

EGM

arrow

2 Sep 2023

12:00 AM

AGM

Announcement Date: 02 Sep, 2023

arrow

27 Aug 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

4 Sep 2023

12:00 AM

BookCloser

arrow

Kabra Drugs Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Kabra Drugs Ltd SHAREHOLDING SNAPSHOT

19 Sep, 2024|07:48 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.00%

Foreign: 0.00%

Indian: 0.00%

Non-Promoter- 1000.00%

Institutions: 0.00%

Non-Institutions: 100.00%

Custodian: 0.00%

Share Price

Kabra Drugs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

6.94

4.39

4.39

4.39

Preference Capital

0

0

0

0

Reserves

-5.86

-5.12

-4.78

-4.6

Net Worth

1.08

-0.73

-0.39

-0.21

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2019Mar-2018

Revenue

0

0

0

1.8

yoy growth (%)

0

0

-100

-76.3

Raw materials

0

0

0

-1.27

As % of sales

0

0

0

70.86

Employee costs

-0.04

0

-0.03

-1.17

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2019Mar-2018

Profit before tax

-0.18

-0.05

-0.16

-1.41

Depreciation

-0.03

-0.03

-0.03

-0.13

Tax paid

0

0

0

0

Working capital

0.1

0

-0.12

-0.9

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2019Mar-2018

Growth matrix (%)

Revenue growth

0

0

-100

-76.3

Op profit growth

198.36

-63.66

-86.72

-334.74

EBIT growth

207.45

-63.16

-86.27

-477.56

Net profit growth

202.1

-63.82

-93

-1,909.97

View Ratios

No Record Found

Kabra Drugs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,846.45

157.994,39,714.12237.820.744,409.7498.75

Divis Laboratories Ltd

DIVISLAB

5,435.65

87.391,45,166.184300.552,063507.93

Cipla Ltd

CIPLA

1,638.45

33.591,33,401.991,055.940.793,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,350.65

75.671,13,724.414690.832,394201.77

Dr Reddys Laboratories Ltd

DRREDDY

6,506.8

26.61,09,604.311,417.20.615,823.91,458.61

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Kabra Drugs Ltd

Management

Register Office

Registrar Office

Whole Time Director & CFO

B V Anatha Kumar

Independent Director

Ananthkumar Shilpa

Independent Director

Churchil Durai M Jebastine

Independent Director

KUNIAMUTHUR NANJAPPAN ANAND

Company Sec. & Compli. Officer

Monika Sanwal

Independent Director

A Anitha

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Kabra Drugs Ltd was incorporated as a Limited Company on August 22, 1989. The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical. The commercial production commenced in 1991. Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P. tHE Company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.The latest addition to the product line is the range of disinfectants which includes hand wash gel, hand sanitizer and antimicrobial gel. In India there are very few manufacturers who are manufacturing the said products. The company is the sole manufacturer of antimicrobial hand wash gel and other disinfectant products in India. The company is also a registered supplier to the Ministry of Defence.With manufacturing and regular supply in the domestic market for injectables, soft gelatin capsules and liquids (oral and external especially alcohol products) the company now looks at the global market. A number of new products have been developed for the same.Kabra Drugs are known to meet the diverse medical needs of patients in Emerging Markets in an innovative, socially responsible and commercially viable manner. Their products are manufactured at state of the art ultra modern plants with latest equipments backed by professional technocrats. These are WHO-GMP, cGMP & Sched
Read More

Company FAQs

What is the Kabra Drugs Ltd share price today?

The Kabra Drugs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹9.14 today.

What is the Market Cap of Kabra Drugs Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kabra Drugs Ltd is ₹9.21 Cr. as of 16 Sep ‘24

What is the PE and PB ratio of Kabra Drugs Ltd?

The PE and PB ratios of Kabra Drugs Ltd is 0 and 2.18 as of 16 Sep ‘24

What is the 52 Week High and Low of Kabra Drugs Ltd?

The 52-week high/low is the highest and lowest price at which a Kabra Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kabra Drugs Ltd is ₹3.2 and ₹9.14 as of 16 Sep ‘24

What is the CAGR of Kabra Drugs Ltd?

Kabra Drugs Ltd's CAGR for 5 Years at 74.19%, 3 Years at 21.07%, 1 Year at 185.63%, 6 Month at 27.12%, 3 Month at 15.55% and 1 Month at 4.94%.

What is the shareholding pattern of Kabra Drugs Ltd?

The shareholding pattern of Kabra Drugs Ltd is as follows:
Promoters - 0.00 %
Institutions - 0.00 %
Public - 100.00 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Center

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp